» Articles » PMID: 1511535

A Review of Assay Methods for Cyclosporin. Clinical Implications

Overview
Specialty Pharmacology
Date 1992 Sep 1
PMID 1511535
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclosporin is a unique immunosuppressive agent with a narrow therapeutic range. The pharmacokinetics of the drug present substantial within- and between-patient variability and drug interactions can significantly alter blood cyclosporin concentrations. Monitoring of cyclosporin concentrations in blood is an invaluable and essential aid in adjusting dosage to ensure adequate immunosuppression while minimising toxicity. The principal rationale behind therapeutic monitoring of cyclosporin is the fact that the incidence of rejection is higher at low cyclosporin concentrations and toxicity occurs more often at high concentrations. In renal transplant recipients, cyclosporin concentrations help to discriminate between insufficient immunosuppression and cyclosporin-induced nephrotoxicity. There are several methods available, both specific and nonspecific, for the routine measurement of cyclosporin. Radioimmunoassay and fluorescence polarisation immunoassay are most widely employed, while high performance liquid chromatography remains the reference procedure. The allegedly specific immunoassays tend to slightly overestimate the actual blood cyclosporin concentrations. There is a need for assay systems capable of measuring the biological activity of cyclosporin. Cyclosporin concentrations should be determined by a specific method, using whole blood as the sample matrix. The routine monitoring of individual cyclosporin metabolites is not warranted, but characterising the metabolite pattern of cyclosporin by concomitant use of a nonspecific and a specific assay can be clinically useful in patients with cyclosporin-associated toxicity or impaired liver function. In organ transplantation, measurement of blood cyclosporin concentration should be continued periodically as long as the therapy continues, whereas monitoring is only indicated in special circumstances in patients with autoimmune and other nontransplant diseases. The assessment of a 'therapeutic window' for cyclosporin is complicated for several reasons and definite target ranges cannot be given. Cyclosporin concentrations should always be interpreted in conjunction with the recent blood concentration history and other relevant clinical and laboratory data.

Citing Articles

Population pharmacokinetics of cyclosporine in transplant recipients.

Han K, Pillai V, Venkataramanan R AAPS J. 2013; 15(4):901-12.

PMID: 23775356 PMC: 3787227. DOI: 10.1208/s12248-013-9500-8.


Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.

Fanta S, Jonsson S, Backman J, Karlsson M, Hoppu K Br J Clin Pharmacol. 2007; 64(6):772-84.

PMID: 17662086 PMC: 2198781. DOI: 10.1111/j.1365-2125.2007.03003.x.


Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation.

Federico S, Carrano R, Capone D, Gentile A, Palmiero G, Basile V Clin Pharmacokinet. 2006; 45(2):169-75.

PMID: 16485913 DOI: 10.2165/00003088-200645020-00003.


Prevention of transplant rejection: current treatment guidelines and future developments.

Perico N, Remuzzi G Drugs. 1997; 54(4):533-70.

PMID: 9339960 DOI: 10.2165/00003495-199754040-00003.


The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Tsunoda S, Aweeka F Clin Pharmacokinet. 1996; 30(2):107-40.

PMID: 8906895 DOI: 10.2165/00003088-199630020-00003.


References
1.
Wong P, Ma J . Specific and nonspecific monoclonal 125I-Incstar assays. Transplant Proc. 1990; 22(3):1166-70. View

2.
Uchida K, Yamada N, Orihara A, Tominaga Y, Tanaka Y, Hayashi S . Minimal low dosage of cyclosporine therapy in renal transplantation by careful monitoring of high-performance liquid chromatography whole blood trough levels. Transplant Proc. 1988; 20(2 Suppl 2):394-401. View

3.
Thomson A, Neild G . Cyclosporin: use outside transplantation. BMJ. 1991; 302(6767):4-5. PMC: 1668781. DOI: 10.1136/bmj.302.6767.4. View

4.
Donnelly J, Soldin S . A radioreceptor assay for the measurement of cyclosporine activity: a preliminary report. Ther Drug Monit. 1989; 11(6):696-700. DOI: 10.1097/00007691-198911000-00015. View

5.
Marsden J, Johnston A, Holt D . Monoclonal antibodies for the radioimmunoassay of cyclosporine. Transplant Proc. 1988; 20(2 Suppl 2):319-22. View